KHPG(SZ:002773)2021-10-27 16:00Financial Performance - Total revenue for Q3 2021 was ¥944,914,964.29, a decrease of 1.02% compared to the same period last year, while year-to-date revenue reached ¥2,844,779,393.27, an increase of 21.16%[2] - Net profit attributable to shareholders for Q3 2021 was ¥232,651,658.21, down 4.83% year-on-year, with a year-to-date net profit of ¥653,141,903.79, up 12.80%[2] - Total operating revenue for Q3 2021 reached CNY 2,844,779,393.27, an increase of 21.1% compared to CNY 2,347,970,518.20 in the same period last year[13] - Net profit for Q3 2021 was CNY 653,141,903.79, representing a 12.8% increase from CNY 579,044,560.00 in Q3 2020[15] - The total comprehensive income for Q3 2021 was CNY 652,729,468.94, compared to CNY 578,384,099.58 in the same quarter last year, an increase of 12.8%[15] Research and Development - R&D expenses increased by 271.44% compared to the same period last year, indicating a significant rise in investment in research and development[6] - R&D expenses surged to CNY 581,985,307.15, a significant increase of 271.5% compared to CNY 156,683,519.77 in the previous year[14] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥432,576,134.61 year-to-date, which is a decrease of 30.59% compared to the previous year[2] - The cash inflow from operating activities for Q3 2021 was CNY 3,212,953,461.35, an increase of 21.4% compared to CNY 2,646,509,743.28 in the same period last year[17] - The net cash flow from operating activities decreased to CNY 432,576,134.61, down 30.6% from CNY 623,247,974.76 in Q3 2020[17] - Cash inflow from investment activities totaled CNY 2,601,621,700.69, a decrease of 23.1% from CNY 3,386,636,059.08 in the previous year[18] - The ending cash and cash equivalents balance was CNY 2,042,318,083.77, up from CNY 1,630,504,954.42 at the end of Q3 2020[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,165,901,894.70, reflecting a 2.35% increase from the end of the previous year[3] - The total assets as of September 30, 2021, amounted to RMB 7,165,901,894.70, an increase from RMB 7,001,158,559.94 at the end of 2020[12] - Total liabilities decreased to CNY 846,399,709.00 from CNY 1,245,342,681.02, reflecting a reduction of 32.1%[13] - Total equity attributable to shareholders increased to CNY 6,319,502,185.70, up from CNY 5,755,815,878.92, marking an increase of 9.8%[13] - The company’s total liabilities and equity remained consistent, indicating stable financial health despite fluctuations in cash flow[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 62,768, with the largest shareholder holding 31.76% of the shares[7] - The company expects to achieve a turnaround in net profit attributable to shareholders by the end of the fiscal year 2021 compared to the previous year[9] Government Support - The company received government subsidies amounting to ¥43,801,507.24 during the reporting period, contributing to its financial performance[4] Company Developments - The company established Chengdu Hongji Biotechnology Co., Ltd. to engage in pharmaceutical wholesale, import and export, and production[10] - The company also formed Sichuan Honghe Biotechnology Co., Ltd. focusing on medical research, cell technology development, and various chemical product manufacturing[10]